Tetra Bio-Pharma Creates the ENJOUCA Business Unit
OTTAWA, ON / ACCESSWIRE / February 3, 2021 / Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced today the creation of a wholly-owned subsidiary called ENJOUCA.
Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories, QIXLEEF can be commercialized as a medical cannabis product. As a result, Tetra s strategy is to launch QIXLEEF under the trademark, ENJOUCA as a medical cannabis product within those territories using its robust clinical package.
ENJOUCA branded products will be distributed through existing medical cannabis channels.
Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1 Clinical Trial to Commence
OTTAWA, ON / ACCESSWIRE / January 29, 2021 /
Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company s Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEF
TM Reborn1
TM clinical trial in cancer patients with breakthrough pain. This is really good news for all of us and in particular for the cancer patients that suffer from breakthrough pain. We aim to initiate this proof-of-concept trial designed to demonstrate that QIXLEEF
Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U S Reborn1(TM) Clinical Trial to Commence theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Helix BioPharma Corp.: Helix Biopharma Corp. Responds to Market Activity
RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Helix is a biopharmaceutical company developing unique therapies in the field of immuno-oncology, for the prevention and treatment of cancer, based on its proprietary technology platform DOS47. Helix is currently listed on the TSX under the symbol HBP . For more information: https://www.helixbiopharma.com
Tetra Bio-Pharma Files New Drug Submission for REDUVO in Canada
Tetra meets another key milestone before the end of the year
OTTAWA, ON / ACCESSWIRE / December 30, 2020 /
Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the New Drug Submission (NDS) for the Dronabinol Soft Gel capsules, has been filed with Health Canada. If successful, it will provide Tetra with its first Drug Identification Number (DIN) for a THC-based prescription drug. The new drug name, REDUVO, is pending approval by Health Canada.
REDUVO will allow Tetra to establish a revenue stream based on a synthetic cannabinoid drug for major markets in Chemotherapy-induced Nausea and Vomiting (CINV). The addressable market is estimated to be $80M CDN by 2022